FDA 483 - BTI Filtration - December 03, 2025

An FDA inspection of BTI Filtration in Oklahoma City, OK, revealed a significant quality system deficiency. The firm failed to perform a required risk analysis for its Class II BTI Filtration Deionization and Carbon Exchange System, which is used in hemodialysis water treatment. This indicates a lack of proper risk management for a critical medical device.